SCHEMBL3365775

SCHEMBL3365775

CC(C)(C)OC(=O)CCCCCCCN

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 4/20 0.50
LMNA P02545 3/20 0.46
THRB P10828 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
PLG P00747 1/20 0.46
ALOX15 P16050 1/20 0.46
SLC6A2 P23975 1/20 0.46
RECQL P46063 1/20 0.46
SLC6A3 Q01959 1/20 0.46
CYP1A2 P05177 2/20 0.45
EPHX2 P34913 1/20 0.43
CYP2D6 P10635 1/20 0.43
NFKB1 P19838 1/20 0.43
BLM P54132 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HDAC1 Q13547 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22834112 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL7342998 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL3661993 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL7697296 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL10382831 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL1952053 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL931564 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
SCHEMBL21611683 1.00 PAOX (0.50) PAOXLMNATHRBKMT2AMEN1
Hydrochloric Acid SCHEMBL23045095 0.98 PAOX (0.48) PAOXLMNATHRBKMT2AMEN1
Bromide SCHEMBL28930592 0.98 PAOX (0.48) PAOXLMNATHRBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119432383-A High-selectivity etching solution for radio frequency chip material 湖北兴福电子材料股份有限公司 2025-02-14 CN claimed
EP-0400290-A1 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors CIBA-GEIGY AG (CH) 1990-12-05 EP claimed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP claimed
US-12528814-B2 Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof NURIX THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
EP-4619037-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT Lerchen, Hans-Georg (DE) 2025-09-24 EP disclosed
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 EP disclosed
CN-119504710-A PROTACs compound for targeted degradation of PRMT5 and application thereof 昆明医科大学 2025-02-25 CN disclosed
CN-119432383-A High-selectivity etching solution for radio frequency chip material 湖北兴福电子材料股份有限公司 2025-02-14 CN disclosed
US-20240423973-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS LERCHEN, HANS-GEORG (DE) 2024-12-26 US disclosed
US-20240425512-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF 280 BIO, INC. (US) 2024-12-26 US disclosed
CN-119143740-A Benzothiophene derivative and preparation method and application thereof 杭州科兴生物化工有限公司 2024-12-17 CN disclosed
US-4914129-A Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups CIBA-GEIGY CORPORATION (US) 1990-04-03 US disclosed
US-4863903-A RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1989-09-05 US disclosed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 US disclosed
US-4719288-A HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1988-01-12 US disclosed
EP-0236734-A2 5-Amino-4-hydroxyvaleryl derivatives substituted by s-containing groups CIBA-GEIGY AG (CH) 1987-09-16 EP disclosed
US-4613676-A PEPTIDES CIBA-GEIGY CORPORATION (US) 1986-09-23 US disclosed
EP-0184550-A2 5-Amino-4-hydroxy valeryl amide derivatives CIBA-GEIGY AG (CH) 1986-06-11 EP disclosed
EP-0144290-A2 Substituted ethylenediamine derivatives CIBA-GEIGY AG (CH) 1985-06-12 EP disclosed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528814-B2 Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof IRAK1, IRAK2, IRAK3 PAOX 2866/4885LMNA 1190/4885THRB 1074/4885
US-20240423973-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS PCNA, TP53, BRCA1 PAOX 2947/4885LMNA 184/4885THRB 1276/4885
US-20240425512-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF KRAS, NRAS, HRAS PAOX 2787/4885LMNA 1913/4885THRB 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.